I

Instituto Rosenbusch SA
BCBA:ROSE

Watchlist Manager
Instituto Rosenbusch SA
BCBA:ROSE
Watchlist
Price: 229.5 ARS -3.97% Market Closed
Market Cap: 9.8B ARS

Relative Value

There is not enough data to reliably calculate the relative value of ROSE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ROSE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
6
vs Industry
78
Median 3Y
0.8
Median 5Y
0.6
Industry
2.7
vs History
23
vs Industry
43
Median 3Y
5.5
Median 5Y
5
Industry
21.6
vs History
44
vs Industry
46
Median 3Y
11.9
Median 5Y
8
Industry
16.9
vs History
11
vs Industry
11
Median 3Y
58.2
Median 5Y
46.3
Industry
22.9
vs History
50
vs Industry
53
Median 3Y
1.6
Median 5Y
1.9
Industry
2.3
vs History
6
vs Industry
80
Median 3Y
0.8
Median 5Y
0.6
Industry
3
vs History
11
vs Industry
75
Median 3Y
1.9
Median 5Y
1.5
Industry
5.6
vs History
26
vs Industry
51
Median 3Y
3.1
Median 5Y
3.1
Industry
13.4
vs History
33
vs Industry
48
Median 3Y
3.7
Median 5Y
3.8
Industry
16.7
vs History
49
vs Industry
47
Median 3Y
14.3
Median 5Y
9.4
Industry
16.1
vs History
39
vs Industry
36
Median 3Y
8.1
Median 5Y
7.8
Industry
18.9
vs History
6
vs Industry
64
Median 3Y
0.9
Median 5Y
0.8
Industry
2

Multiples Across Competitors

ROSE Competitors Multiples
Instituto Rosenbusch SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AR
Instituto Rosenbusch SA
BCBA:ROSE
9.8B ARS 1.6 10.7 6.2 7.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.2 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
511.7B USD 5.6 20.4 16.6 21.6
CH
Roche Holding AG
SIX:ROG
269.5B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 5 31 109.2 159.8
CH
Novartis AG
SIX:NOVN
216.4B CHF 4.8 18.9 11.9 15.4
US
Merck & Co Inc
NYSE:MRK
270.2B USD 4.2 14.2 10.1 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.6 11.6 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
AR
I
Instituto Rosenbusch SA
BCBA:ROSE
Average P/E: 23.4
10.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AR
I
Instituto Rosenbusch SA
BCBA:ROSE
Average EV/EBITDA: 400.7
6.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.2
10%
10.9
CH
Novartis AG
SIX:NOVN
11.9
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AR
I
Instituto Rosenbusch SA
BCBA:ROSE
Average EV/EBIT: 1 713.2
7.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.6
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.8
23%
6.9
CH
Novartis AG
SIX:NOVN
15.4
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4